Paper42474263
A comprehensive review of small molecule drugs approved by the FDA in 2025: advance and prospect.
Bai YR and 6 others. J Enzyme Inhib Med Chem, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. A comprehensive review of small molecule drugs approved by the FDA in 2025: advance and prospect. Papers, record 42474263. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42474263
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- A comprehensive review of small molecule drugs approved by the FDA in 2025: advance and prospect.
- PubMed
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Small Molecule Libraries | Major topic |
| Drug Approval | Major topic |
| United States | |
| Humans | |
| United States Food and Drug Administration | |
| Structure-Activity Relationship | |
| Molecular Structure | |
| Drug Design |
Source PubMed
References95
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 38101437 | Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trial. | Lancet Respir Med | 2024 | https://conductscience.org/library/papers/38101437 | PubMed |
| 2 | 38400780 | Safety and pharmacokinetics of ONC201 (dordaviprone) administered two consecutive days per week in pediatric patients with H3 K27M-mutant glioma. | Neuro Oncol | 2024 | https://conductscience.org/library/papers/38400780 | PubMed |
| 3 | 39700833 | Real life data of ONC201 (dordaviprone) in pediatric and adult H3K27-altered recurrent diffuse midline glioma: Results of an international academia-driven compassionate use program. | Eur J Cancer | 2025 | https://conductscience.org/library/papers/39700833 | PubMed |
| 4 | 40069319 | Upcoming FDA approval decisions in Q2 2025. | Nat Rev Drug Discov | 2025 | https://conductscience.org/library/papers/40069319 | PubMed |
| 5 | 35961460 | Discovery of vimseltinib (DCC-3014), a highly selective CSF1R switch-control kinase inhibitor, in clinical development for the treatment of Tenosynovial Giant Cell Tumor (TGCT). | Bioorg Med Chem Lett | 2022 | https://conductscience.org/library/papers/35961460 | PubMed |
| 6 | 36768346 | Artificial Intelligence and Machine Learning Technology Driven Modern Drug Discovery and Development. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/36768346 | PubMed |
| 7 | 8676339 | 2,4-Diarylpyrrolidine-3-carboxylic acids--potent ETA selective endothelin receptor antagonists. 1. Discovery of A-127722. | J Med Chem | 1996 | https://conductscience.org/library/papers/8676339 | PubMed |
| 8 | 20686482 | Type IIA topoisomerase inhibition by a new class of antibacterial agents. | Nature | 2010 | https://conductscience.org/library/papers/20686482 | PubMed |
| 9 | 38822758 | Efficacy and Safety of Taletrectinib in Chinese Patients With ROS1+ Non-Small Cell Lung Cancer: The Phase II TRUST-I Study. | J Clin Oncol | 2024 | https://conductscience.org/library/papers/38822758 | PubMed |
| 10 | 39869433 | New Oral Selective Estrogen Receptor Degraders Redefine Management of Estrogen Receptor-Positive Breast Cancer. | Annu Rev Med | 2025 | https://conductscience.org/library/papers/39869433 | PubMed |
| 11 | 40030100 | HER2-Selective Tyrosine Kinase Inhibitor, Zongertinib (BI 1810631), in Patients With Advanced/Metastatic Solid Tumors With HER2 Alterations: A Phase Ia Dose-Escalation Study. | J Clin Oncol | 2025 | https://conductscience.org/library/papers/40030100 | PubMed |
| 12 | 39824516 | Discovery of STX-721, a Covalent, Potent, and Highly Mutant-Selective EGFR/HER2 Exon20 Insertion Inhibitor for the Treatment of Non-Small Cell Lung Cancer. | J Med Chem | 2025 | https://conductscience.org/library/papers/39824516 | PubMed |
| 13 | 39248702 | Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers. | Cancer Discov | 2025 | https://conductscience.org/library/papers/39248702 | PubMed |
| 14 | 40266575 | Rilzabrutinib in Antihistamine-Refractory Chronic Spontaneous Urticaria: The RILECSU Phase 2 Randomized Clinical Trial. | JAMA Dermatol | 2025 | https://conductscience.org/library/papers/40266575 | PubMed |
| 15 | 39196032 | Aficamten is a small-molecule cardiac myosin inhibitor designed to treat hypertrophic cardiomyopathy. | Nat Cardiovasc Res | 2024 | https://conductscience.org/library/papers/39196032 | PubMed |
| 16 | 34002056 | Kinase drug discovery 20 years after imatinib: progress and future directions. | Nat Rev Drug Discov | 2021 | https://conductscience.org/library/papers/34002056 | PubMed |
| 17 | 39940712 | Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/39940712 | PubMed |
| 18 | 34606259 | Discovery of Aficamten (CK-274), a Next-Generation Cardiac Myosin Inhibitor for the Treatment of Hypertrophic Cardiomyopathy. | J Med Chem | 2021 | https://conductscience.org/library/papers/34606259 | PubMed |
| 19 | 32348841 | Tetrahydrobiopterin in energy metabolism and metabolic diseases. | Pharmacol Res | 2020 | https://conductscience.org/library/papers/32348841 | PubMed |
| 20 | 37211904 | New drug approvals for 2022: Synthesis and clinical applications. | Med Res Rev | 2023 | https://conductscience.org/library/papers/37211904 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 0 citations.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 42883213 | Small-Molecule Drugs Approved by the FDA in 2025. | Molecules | 2026 | https://conductscience.org/library/papers/42883213 |
Source PubMed
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42474263
GET https://conductscience.org/api/papers/v1/42474263/references?page=2